Alexei F Kisselev

List of Publications by Year
in descending order

35 papers	3,935 citations	236925 25 h-index	361022 35 g-index
35 all docs	35 docs citations	35 times ranked	4053 citing authors

#	Article	IF	Citations
1	Proteasome inhibitors: from research tools to drug candidates. Chemistry and Biology, 2001, 8, 739-758.	6.0	1,053
2	Proteasome Inhibitors: An Expanding Army Attacking a Unique Target. Chemistry and Biology, 2012, 19, 99-115.	6.0	464
3	Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate. Journal of Biological Chemistry, 2006, 281, 8582-8590.	3.4	359
4	Monitoring Activity and Inhibition of 26S Proteasomes with Fluorogenic Peptide Substrates. Methods in Enzymology, 2005, 398, 364-378.	1.0	294
5	Proteasome Active Sites Allosterically Regulate Each Other, Suggesting a Cyclical Bite-Chew Mechanism for Protein Breakdown. Molecular Cell, 1999, 4, 395-402.	9.7	262
6	The Caspase-like Sites of Proteasomes, Their Substrate Specificity, New Inhibitors and Substrates, and Allosteric Interactions with the Trypsin-like Sites. Journal of Biological Chemistry, 2003, 278, 35869-35877.	3.4	167
7	Binding of Hydrophobic Peptides to Several Non-catalytic Sites Promotes Peptide Hydrolysis by All Active Sites of 20 S Proteasomes. Journal of Biological Chemistry, 2002, 277, 22260-22270.	3.4	161
8	Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites. Chemistry and Biology, 2009, 16, 1278-1289.	6.0	147
9	Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib. Chemistry and Biology, 2011, 18, 608-618.	6.0	94
10	Structure-Based Design of Î²1i or Î²5i Specific Inhibitors of Human Immunoproteasomes. Journal of Medicinal Chemistry, 2014, 57, 6197-6209.	6.4	89
11	A Set of Activityâ€Based Probes to Visualize Human (Immuno)proteasome Activities. Angewandte Chemie - International Edition, 2016, 55, 4199-4203.	13.8	86
12	Inhibition of the Proteasome Î²2 Site Sensitizes Triple-Negative Breast Cancer Cells to Î²5 Inhibitors and Suppresses Nrf1 Activation. Cell Chemical Biology, 2017, 24, 218-230.	5.2	83
13	Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites. Journal of Medicinal Chemistry, 2013, 56, 1262-1275.	6.4	79
14	Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Current Opinion in Chemical Biology, 2014, 23, 16-22.	6.1	56
15	Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors*. Journal of Biological Chemistry, 2010, 285, 40125-40134.	3.4	55
16	A panel of subunit-selective activity-based proteasome probes. Organic and Biomolecular Chemistry, 2010, 8, 2719.	2.8	47
17	Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib. PLoS ONE, 2013, 8, e56132.	2.5	47
18	Why the Structure but Not the Activity of the Immunoproteasome Subunit Low Molecular Mass Polypeptide 2 Rescues Antigen Presentation. Journal of Immunology, 2012, 189, 1868-1877.	0.8	43

#	Article	IF	Citations
19	A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3402-3405.	2.2	42
20	The novel Â2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica, 2015, 100, 1350-1360.	3.5	39
21	Incorporation of Fluorinated Phenylalanine Generates Highly Specific Inhibitor of Proteasomeâ€™s Chymotrypsin-like Sites. Journal of Medicinal Chemistry, 2010, 53, 2319-2323.	6.4	32
22	Joining the Army of Proteasome Inhibitors. Chemistry and Biology, 2008, 15, 419-421.	6.0	31
23	Discovery of a potent and highly Î²1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones. Organic and Biomolecular Chemistry, 2012, 10, 181-194.	2.8	28
24	Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors. Molecular Biology Reports, 1997, 24, 69-75.	2.3	27
25	An inhibitor of proteasome Î²2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Advances, 2018, 2, 2443-2451.	5.2	27
26	Site-Specific Proteasome Inhibitors. Biomolecules, 2022, 12, 54.	4.0	24
27	Structure-Based Design of Inhibitors Selective for Human Proteasome Î²2c or Î²2i Subunits. Journal of Medicinal Chemistry, 2019, 62, 1626-1642.	6.4	23
28	Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLLâ€“AF4 fusion protein. Scientific Reports, 2021, 11, 10883.	3.3	20
29	Structure-Based Design of Î²5c Selective Inhibitors of Human Constitutive Proteasomes. Journal of Medicinal Chemistry, 2016, 59, 7177-7187.	6.4	19
30	DNA-Histone Cross-Links: Formation and Repair. Frontiers in Cell and Developmental Biology, 2020, 8, 607045.	3.7	12
31	A Set of Activityâ€Based Probes to Visualize Human (Immuno)proteasome Activities. Angewandte Chemie, 2016, 128, 4271-4275.	2.0	9
32	A Novel Bullet Hits the Proteasome. Cancer Cell, 2013, 24, 691-693.	16.8	8
33	Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity. Analytical Biochemistry, 2014, 451, 1-3.	2.4	3
34	Asymmetric Synthesis of Lysine Analogues with Reduced Basicity, and their Incorporation into Proteasome Inhibitors. European Journal of Organic Chemistry, 2017, 2017, 5921-5934.	2.4	3
35	Structureâ€Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits. ChemBioChem, 2020, 21, 3220-3224.	2.6	2